Study in a Sentence: A new multi-component, transformer-based, open-source AI model, Boltz-2, predicts protein–drug binding ...

Meeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the ...

Simulations Plus, Inc. (NASDAQ:SLP) is one of the top 10 medical AI companies to buy according to analysts. On July 29, the ...

Researchers from the Germans Trias i Pujol Research Institute (IGTP) have published a study in Scientific Reports that ...

Researchers from the Cancer Genetics and Epigenetics group at IGTP have published a study in Scientific Reports presenting a ...

Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU.

This review explores how generative AI, through models like VAEs, GANs, transformers, and diffusion networks is ...

A professor at the Indiana Univesity Luddy School of Informatics, Computing and Engineering has co-authored a paper ...

The modelling and simulation research team at the NRC's Automotive and Surface Transportation Research Centre is a leader in ...

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

Insiders at the Food and Drug Administration are ringing alarm bells over the agency's use of an AI to fast-track drug ...